undamentalytics Newsletter
Sign in

Goodrx Holdings, Inc. revenue

Goodrx Holdings, Inc.'s revenue was $797m in fiscal 2025, up 0.6% on the year before. Since fiscal 2018 ($250m) it has grown at a compound 18.0% a year. Over the last twelve months it was $785m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue250388551745767750792797785
Growth on the year before—+55.6%+41.9%+35.4%+2.8%−2.1%+5.6%+0.6%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Prescription Transactions Revenue $544M 68.3% ▼ 5.8%
Pharma Direct Revenue $151M 19.0% ▲ 41.2%
Subscription Revenue $83.8M 10.5% ▼ 3.2%
Other Revenue $17.7M 2.2% ▼ 15.8%

From Goodrx Holdings, Inc.'s 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Health Care Technology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Goodrx Holdings, Inc. $785m -1.8% 1.8%
Doximity, Inc. $656m 11.2% 14.5%
Phreesia, Inc. $508m 12.9% 16.7%
Omnicell, Inc. $1.25bn 8.5% 0.3%
Waystar Holding Corp. $1.26bn 21.4% —
Genedx Holdings Corp. $454m 25.4% 24.3%

Compare with peers

Head to head: DOCS vs GDRXGDRX vs PHRGDRX vs OMCLGDRX vs WAY

More: Health Care Technology stocks compared, Health Care sector, rankings of US companies

Figures from Goodrx Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Goodrx Holdings, Inc.